Introducing the Clinical and Referral Guidance Hub

September 21, 2026

South Eastern Melbourne PHN has launched the Clinical and Referral Guidance Hub (the Hub), a new platform providing primary care professionals in south east Melbourne with centralised access to local referral information and clinical guidance. 

The Hub brings together key resources in one place, helping clinicians quickly find reliable, up-to-date information to support patient care, without needing to navigate multiple systems.

 Through the platform, primary care professionals can access free clinical guidance via Therapeutic Guidelines, alongside referral information from local public health networks. The Hub also includes direct links to trusted resources such as Healthdirect and Statewide Referral Criteria.

 The Hub has been developed in collaboration with clinicians across the region, with input gathered through in-person workshops and online testing to ensure it is practical and user-friendly.

 “The Clinical and Referral Guidance Hub is about making it easier for primary care professionals to find the trusted information they need. It has been shaped by local clinicians, and their feedback will continue to guide how the platform evolves.”
Michael Spencer, Interim CEO, South Eastern Melbourne PHN

 SEMPHN will continue to seek feedback from users as the Hub is rolled out across the region.

Learn more and register to access the Hub here

Latest news

September 17, 2026
Dementia Action Week is held each September to raise awareness of dementia, reduce stigma and build greater understanding of the experiences of people living with dementia, their families and carers.
September 15, 2026
As warmer weather approaches, now is a timely opportunity to review your vaccine storage practices and complete your essential cold chain management audit.
September 10, 2026
Sublocade® (long acting injectable buprenorphine) will be discontinued in Australia after 31 December 2026. The decision is not related to safety, quality or efficacy concerns and people currently receiving Sublocade® should continue their treatment as prescribed.